Juan López-Belmonte, CEO of ROVI and vice-president of Farmaindustria, highlighted at the Spain Investors Day the potential of our country as an investment destination for reindustrialisation, highlighting the pharmaceutical sector for its ability to play a decisive role in this regard. “Spain can become a hub for the production of medicines for Europe,” said Juan López-Belmonte.

The sector’s commitment is clear and forward-looking. Over the next three years, pharmaceutical companies plan to invest more than 2.7 billion euros in Spain alone to strengthen manufacturing capacities for strategic medicines, new therapies and vaccines, the digitalisation of production processes and energy efficiency.

These investments must be added to the 4.5 billion euros that the industry will allocate to research and development for the same period, as well as a further 1 billion euros planned for global activities of technological or strategic content. “At Farmaindustria we are working to make Spain a champion in the chemical sector,” said López-Belmonte.

